Novo Nordisk vs Eli Lilly obesity drug market competition
The developments in this story so far, most recent first.
-
· date approximate Development
Novo Nordisk raises full-year profit and revenue forecasts
-
· date approximate Development
Novo Nordisk and Eli Lilly Obesity Drug Rivalry Intensifies Ahead of Financial Results
-
· date approximate Background
Novo Nordisk ADR price climbed above the 50 dollar mark.
No separate article for this desk or language yet.
-
· date approximate Background
Novo Nordisk shares reached a low point.
No separate article for this desk or language yet.
-
· date approximate Background
Novo Nordisk expected a revenue decline of up to 13 percent at the beginning of the year.
No separate article for this desk or language yet.
-
· date approximate Background
The oral version of Wegovy was launched in the US.
The oral version of the weight-loss drug Wegovy, produced by the Danish company Novo Nordisk, was launched in the United States in January.
Since its release, demand for the oral pill has been stronger than many analysts initially expected. Some market experts assess that this strong demand could lead to a limited improvement in Novo Nordisk's annual forecast.
-
· date approximate Background
The price of Novo Nordisk ADRs has declined by 14 percent since the end of 2025.
No separate article for this desk or language yet.
-
· date approximate Background
Novo Nordisk faced profit expectation cuts, management changes, and stock losses throughout the year.
Throughout 2025, Novo Nordisk faced a series of setbacks including consecutive cuts to its profit expectations, which were attributed to increasing price pressure. These financial challenges occurred alongside management changes and significant losses in the company's stock value.